1. Scrip
  2. >>Business

US FDA Approves Subcutaneous Opdivo, Extending Key BMS Franchise Into 2030s

Injection Cleared 10 Years After I.V. Product

 
• By Mandy Jackson

With loss of exclusivity for Opdivo looming in 2028, Opdivo Qvantig will help BMS retain at least some of the revenue for its brand-name blockbuster after biosimilars for the I.V. version hit in 2029.

Opdivo Qvantig is crucial to Bristol's post-Opdivo loss of exclusivity revenue (Shutterstock)

Bristol Myers Squibb’s Opdivo Qvantig, the new subcutaneous version of its PD-1 inhibitor Opdivo (nivolumab), will be available starting in early January with a list price that is at parity with the original I.V. version of Opdivo, BMS chief commercialization officer Adam Lenkowsky told Scrip.

Key Takeaways
  • The US FDA approved Bristol’s subcutaneous version of its PD-1 inhibitor Opdivo, which will be available in early January and priced at parity with the original I.V. formulation.

The FDA approved Opdivo Qvantig (nivolumab and hyaluronidase) on 27 December for all of the cancer indications included in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Scrip

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 
• By Jessica Merrill

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

Concentra Picks Up Cargo In Latest Troubled Biotech Buyout

 
• By Alaric DeArment

The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.

Venture Funding Plummets In Q2 As Mega-Rounds Falter

 
• By Mandy Jackson

Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.